MA

agilon health, inc. investors: Please contact the Portnoy Law Firm to recover your losses; May 28, 2024 deadline

Retrieved on: 
Thursday, May 2, 2024
Patient, Pharmaceutical industry

investors that a lawsuit was filed on behalf of investors that purchased agilon securities between April 15, 2021 and February 27, 2024, inclusive (the “Class Period”).

Key Points: 
  • investors that a lawsuit was filed on behalf of investors that purchased agilon securities between April 15, 2021 and February 27, 2024, inclusive (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Thursday, May 2, 2024
Webcast

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 9, 2024, at 4:30 p.m.

Key Points: 
  • WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 9, 2024, at 4:30 p.m.
  • ET to discuss its financial results for the first quarter ended March 31, 2024, and recent business highlights.
  • A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion.
  • Those who plan on participating are advised to join 15 minutes prior to the start time.

Aware Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
International, Law enforcement, Machine learning, Conference, Artificial intelligence, Data science, Federation, Government, AWRE, Acquisition, ATM, Growth, Training, Video game

BURLINGTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Aware, Inc. (NASDAQ: AWRE), a global biometric platform company that uses data science, machine learning, and artificial intelligence to tackle everyday business and identity challenges through biometric solutions, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • BURLINGTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Aware, Inc. (NASDAQ: AWRE), a global biometric platform company that uses data science, machine learning, and artificial intelligence to tackle everyday business and identity challenges through biometric solutions, today reported financial results for the first quarter ended March 31, 2024.
  • Maintained a strong balance sheet with cash, cash equivalents, and marketable securities of $28.5 million as of March 31, 2024.
  • Recurring revenue for the first quarter of 2024 totaled $3.145 million, an increase of 3% compared to $3.062 million in the first quarter of 2023.
  • Aware management will host a webcast today, May 2, 2024, at 5:00 p.m. Eastern time to discuss these results and provide an update on business conditions.

LeMaitre Q1 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Table, Internet, Webcast, GAAP, PIN

On April 30, 2024, the Company's Board of Directors approved a quarterly dividend of $0.16/share of common stock.

Key Points: 
  • On April 30, 2024, the Company's Board of Directors approved a quarterly dividend of $0.16/share of common stock.
  • The dividend will be paid on May 30, 2024, to shareholders of record on May 16, 2024.
  • On February 21, 2024, the Company's Board of Directors authorized the repurchase of up to $50.0mm of the Company’s common stock.
  • A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, May 2, 2024
Sale, American Academy, Episcopal conference, MDA, Research, Muscular Dystrophy Association, DMD, Conference, Therapy, DYN, DM1, G&A, Pharmaceutical industry

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights.

Key Points: 
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights.
  • Research and development (R&D) expenses: R&D expenses were $44.5 million for the quarter ended March 31, 2024, compared to $37.5 million for the quarter ended March 31, 2023.
  • General and administrative (G&A) expenses: G&A expenses were $24.6 million for the quarter ended March 31, 2024, compared to $7.9 million for the quarter ended March 31, 2023.
  • Net loss: Net loss for the quarter ended March 31, 2024 was $65.6 million, or $0.81 per basic and diluted share.

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, May 2, 2024
Investment, Research, Fulvestrant, HR, Patient, Genentech, Therapy, Pharmaceutical industry

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financial results and corporate highlights.

Key Points: 
  • CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financial results and corporate highlights.
  • “We have started 2024 with a focus on maintaining strong execution across our portfolio,” said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
  • Revenue: Revenue was $10.0 million for the first quarter of 2024, as compared to $0.2 million for the first quarter of 2023.
  • R&D Expenses: Research and development expenses were $82.4 million for the first quarter of 2024, as compared to $82.8 million for the first quarter of 2023.

Berman Tabacco Announces Investigation of PowerSchool Holdings LLC formerly known as Severin Holdings, LLC. for Potential Securities Law Violations

Retrieved on: 
Thursday, May 2, 2024

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by PowerSchool Holdings LLC (“Holdings LLC”), formerly known as Severin Holdings, LLC.

Key Points: 
  • BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by PowerSchool Holdings LLC (“Holdings LLC”), formerly known as Severin Holdings, LLC.
  • (“PowerSchool” or the “Company”) (NYSE: PWSC).

iRhythm Technologies Announces First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
EKG, ACC, HRS, IRTC, Traction, Growth, Patient, Heart failure, SAN, Interest, Pharmaceutical industry

SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024.

Key Points: 
  • SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024.
  • Revenue for the first quarter of 2024 was $131.9 million, up 18.4% from $111.4 million during the same period in 2023.
  • Operating expenses for the first quarter of 2024 were $125.7 million, compared to $115.2 million for the same period in 2023.
  • Adjusted operating expenses for the first quarter of 2024 were $125.7 million, compared to $109.5 million during the same period in 2023.

Great Elm Capital Corp. Announces First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
CLO, GECCO, Total, Investment, Security (finance)

During the quarter ended March 31, 2024, we deployed approximately $64.2 million into 29 investments(1) at a weighted average current yield of 12.5%.

Key Points: 
  • During the quarter ended March 31, 2024, we deployed approximately $64.2 million into 29 investments(1) at a weighted average current yield of 12.5%.
  • Net expenses for the quarter ended March 31, 2024 were approximately $5.7 million, or $0.66 per share.
  • Net realized and unrealized losses for the quarter ended March 31, 2024 were approximately $3.7 million, or $0.42 per share.
  • The second quarter distribution will be payable on June 28, 2024 to stockholders of record as of June 14, 2024.